Compare PEB & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEB | RAPP |
|---|---|---|
| Founded | 2009 | 2022 |
| Country | United States | United States |
| Employees | 52 | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | 2024 |
| Metric | PEB | RAPP |
|---|---|---|
| Price | $19.21 | $41.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | $13.30 | ★ $48.50 |
| AVG Volume (30 Days) | ★ 2.3M | 433.0K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.25 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.30 | $13.64 |
| 52 Week High | $19.93 | $44.28 |
| Indicator | PEB | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 58.40 | 52.52 |
| Support Level | $17.64 | $38.55 |
| Resistance Level | $19.68 | $43.70 |
| Average True Range (ATR) | 0.51 | 2.88 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 67.47 | 41.38 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.